Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441337 · ClinicalTrials.gov registry record · Phase 1
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
A Phase 1 study of Prostate Cancer and Colorectal Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 4
- Study locations
NCT00441337: Completed Phase 1 study of Prostate Cancer and Colorectal Cancer, sponsored by Bristol-Myers Squibb.
NCT00441337 is a Phase 1 study of Prostate Cancer and Colorectal Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 39 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00441337, a Phase 1 study of Prostate Cancer and Colorectal Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 4
- Study locations
Study Summary
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer
Primary Outcome
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grad
Conditions Studied
Interventions
- BIOLOGICAL MDX-1106
Study Locations (4)
Maryland
- Johns Hopkins Unv., School of Medicine - Baltimore
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University School of Medicine - Barnes Jewish Hospital - St Louis
North Carolina
- Carolina BioOncology Institute, PLLC - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00441337 record still lists
NCT00441337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower).
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MDX-1106 is the first listed.
NCT00441337 reports a single indexed study location in Maryland, Michigan, Missouri.
Frequently Asked Questions
What is clinical trial NCT00441337 about?
NCT00441337 is a clinical study titled "A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies". To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer
What is the current status of trial NCT00441337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2006-08. Estimated completion is 2009-11.
What conditions does trial NCT00441337 study?
This clinical trial studies the following conditions: Prostate Cancer, Colorectal Cancer, Carcinoma, Non-Small Cell Lung, Renal Cancer, Malignant Melanoma.
What interventions are being tested in trial NCT00441337?
The interventions under investigation include: MDX-1106 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00441337?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00441337 being conducted?
This trial has 4 study locations across Maryland, Michigan, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00441337's enrollment target sits among peer trials
39 536th of 735 higher than 199 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia